HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Preischemic administration of ribose to delay the onset of irreversible ischemic injury and improve function: studies in normal and hypertrophied hearts.

Abstract
Compared with normal hearts, those with pathology (hypertrophy) are less tolerant of metabolic stresses such as ischemia. Pharmacologic intervention administered prior to such stress could provide significant protection. This study determined, firstly, whether the pentose sugar ribose, previously shown to improve postischemic recovery of energy stores and function, protects against ischemia when administered as a pretreatment. Secondly, the efficacy of this same pretreatment protocol was determined in hearts with pathology (hypertrophy). For study 1, Sprague-Dawley rats received equal volumes of either vehicle (bolus i.v. saline) or ribose (100 mg/kg) before global myocardial ischemia. In study 2, spontaneously hypertensive rats (SHR; blood pressure approximately 200/130) with myocardial hypertrophy underwent the same treatment protocol and assessments. In vivo left ventricular function was measured and myocardial metabolites and tolerance to ischemia were assessed. In normal hearts, ribose pretreatment significantly elevated the heart's energy stores (glycogen), and delayed the onset of irreversible ischemic injury by 25%. However, in vivo ventricular relaxation was reduced by 41% in the ribose group. In SHR, ribose pretreatment did not produce significant elevations in the heart's energy or improvements in tolerance to global ischemia, but significantly improved ventricular function (maximal rate of pressure rise (+dP/dt(max)), 25%; normalized contractility ((+dP/dt)/P), 13%) despite no change in hemodynamics. Thus, administration of ribose in advance of global myocardial ischemia does provide metabolic benefit in normal hearts. However, in hypertrophied hearts, ribose did not affect ischemic tolerance but improved ventricular function.
AuthorsW Jack Wallen, Michael P Belanger, Carin Wittnich
JournalCanadian journal of physiology and pharmacology (Can J Physiol Pharmacol) Vol. 81 Issue 1 Pg. 40-7 (Jan 2003) ISSN: 0008-4212 [Print] Canada
PMID12665256 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cardiotonic Agents
  • Phosphocreatine
  • Ribose
  • Adenosine Triphosphate
  • Glycogen
Topics
  • Adenosine Triphosphate (metabolism)
  • Anaerobic Threshold (drug effects, physiology)
  • Animals
  • Cardiotonic Agents (administration & dosage, metabolism)
  • Disease Models, Animal
  • Drug Administration Schedule
  • Glycogen (metabolism)
  • Hypertension (complications, physiopathology)
  • Hypertrophy, Left Ventricular (complications, drug therapy, physiopathology)
  • Injections, Intravenous
  • Male
  • Myocardial Ischemia (physiopathology, prevention & control)
  • Myocardium (metabolism)
  • Phosphocreatine (metabolism)
  • Rats
  • Rats, Sprague-Dawley
  • Ribose (administration & dosage, metabolism)
  • Structure-Activity Relationship
  • Ventricular Function, Left (drug effects, physiology)
  • Ventricular Function, Right (drug effects, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: